Page 113 - 82_02

VM, Trojanowski, JQ. Nitration of tau protein is
linked to neurodegeneration in tauopathies. Am J
Pathol 2003;163(3): 1021-31.
39. Sussman JL, Harel M, Frolow F., Oefner, C, Goldman
A, Toker L, Silman I. Atomic structure of
Acetylcholinesterase from Torpedo Californica: a
prototypic acetylcholine-binding protein. Science
1991;253: 872-9.
40. Guzman M. Cannabinoides: del laboratorio a la clínica.
Biojournal net 2006;4: 1-6.
41. Caffarel MM, Moreno-Bueno G, Cerutti C, Palacios J,
Guzmán M, Mechta Grigoriou F, Sánchez C. JunD is
involved in the antiproliferative effect of 9-
tetrahydrocannabinol on human breast cancer cells.
Oncogene 2008;27: 5033-44.
42. Institute of Medicine. Marijuana and medicine
[formato electrónico] 1999; 196(196) [consultado
03/06/2003]. Disponible en:
http://www.bob.nap.edu/books/0309071550/html
43. Duran M, Laporte JR, Capellà D. Ús terapèutic del
cannabis i els seus derivats. Barcelona: Informe
preparado por la Fundació Institut Català de
Farmacologia para el Departament de Sanitat i
Seguretat Social de la Generalitat de Catalunya, 2003.
44. Piomelli D, Giuffrida A, Calignano A, Rodríguez de
Fonseca F. The endocannabinoid system as target for
therapeutic drugs. Trends Pharmacol Sci 2000;21:
218-24.
45. Salim K, Schneider U, Burstein S, Hoy L, Karst M.
Pain measurements and side effect profile of the novel
cannabinoid ajulemic acid. Neuropharmacology
2005;48: 1164-71.
46. Karst M, Salim K, Burstein S, Conrad I, Hoy L,
Schneider U. Analgesic effect of the synthetic
cannabinoid CT-3 on chronic neuropathic pain. JAMA
2003; 290:1757-62.
47. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL,
Norsted BD, Wilcox GL, et al. A cannabinoid agonist
differentially attenuates deep tissue hyperalgesia in
animal models of cancer and inflammatory muscle
pain. Pain 2003;103: 175-86.
48. Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal
cannabinoid-1-receptors following nerve injury
enhances the effects of Win 55, 212-2 on neuropathic
pain behaviors in rats. Pain 2003;105: 275-83.
49. Maldonado R, Valverde O. Participation of the opioid
system in cannabinoidinduced. anticiception and
emotional-live responses. Eur Neuropsychopharmacol
2003;13: 401-10.
50. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O,
Ozkan Y, et al. Topical cannabinoid enhances topical
morphine antinociception. Pain 2003;105: 303-8.
51. Eshhar N, Striem S, Biegon A. HU-211, a non-
psychotropic cannabinoid, rescues cortical neurones
from excitatory amino acid toxicity in culture.
Neuroreport 1993;5(3): 237-40.
228 @Real Academia Nacional de Farmacia. Spain
José María Sánchez Montero
52. Skaper SD, Buriani A, Dal Toso R, Petrelli L,
Romanello S, Facci L, et al. The Aliamide
palmitoylethanolamide and cannabinoids, but not
anandamide, are protective in a delayed postglutamate
paradigm of excitoxicity death in cerebellar granule
neurons. Proc Nat Acad (USA) 1996;93(9): 3984-9.
53. Shen M. Cannabinoid receptor agonists protect from
exitoxicity. Molecular Pharmacol 1998;54: 459-62.
54. Abood ME, Rizvi G, Sallapudi N, McAllister SD.
Activation of CB1 cannabinoid receptor protects
cultured mouse spinal neurons against exitoxicity.
Neuroscience Lett 2001;309(3): 97-201.
55. Van Der Stelt M, Veldhuis WB, Bar PR, Veldink GA,
Vliegenthart JF, Nicolay K. Neuroprotection by Delta
9-tetrahydrocannabinol, the main active compound in
marijuana, against ouabain-induced in vivo
excitoxicity. J Neurosci 2001;21(17): 6475-9.
56. Van Der Stelt M, Veldhius WB, van Haaften GW,
Fezza F, Bisogno T, Bar PR, et al. Exogenous
anandamide protects rat brain against acute neuronal
injury in vivo. J Neurosci 2001;21(22): 8765-71.
57. Nagayama T, Sinor AD, Simon RP, Chen J, Graham
SH, Jin K, et al. Cannabinoids and neuroprotection in
global and focal cerebral ischemia and in neuronal
cultures. J Neurosci 1999;9(8): 2987-95.
58. Sinor AD, Irvin SM, Greenberg DA.
Endocannabinoids protect cerebral cortical neurons
from in vitro ischemia in rats. Neurosci Lett
2000;278(3): 157-60.
59. Leker RR, Shohami E, Abramsky O, Ovadia H, et al.
Dexanabinol: a novel neuroprotective drug in
experimental focal cerebral ischemia. J Neurol Sci
1999;162(2): 114-9.
60. Mauler F, Mittendorf J, Horvath E, De Vry J.
Characterization of the diarylether sulfonylester(-)-
(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-
trifluoro-1-sulfanote (BAY 38-7271) as a potent
cannabinoid receptor agonist with neuroprotective
properties. J Pharmacol Exp Ther 2002;302(1): 359-
68.
61. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I,
Berrendero F, Manzanares J, et al. Anandamide, but
not 2-arachidonoylglycerol, accumulates during in
vivo neurodegeneration. J Neurochem 2001;78(6):
1415-27.
62. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur
T. Cytokine production in the brain following closed
head injury after head injury: dexanabinol (HU-211) is
a novel TNF-alpha inhibitor and an effective
neuroprotectant. J Neuroimmunol 1997;72(2): 169-77.
63. Duran M, Laporte JR, Capellà D. Novedades sobre las
potencialidades terapéuticas del Cannabis y el sistema
cannabinoide. Med Clin 2004;122(10): 390-398. Di
Marzo V. Endocannabinoids: endogenous cannabinoid
receptor ligands with neuromodulatory action. Trends
Neurosci 1998;21: 521-8.